Financial Data and Key Metrics Changes - Atara Biotherapeutics ended 2019 with cash, cash equivalents, and short-term investments totaling $259.1 million, down from $282.9 million as of September 30, 2019 [21] - Proforma cash and investments as of December 31, 2019, including ATM and option exercise proceeds from January 2020, was $282.7 million [21] Business Line Data and Key Metrics Changes - The company is conducting a Phase 3 clinical trial with tab-cel for patients with EBV-associated PTLD, with 38 sites actively enrolling patients in the U.S. and Australia [8][9] - The overall response rate for the HCT cohort in the tab-cel study was 55%, with a two-year estimated overall survival of 79% [11] - For the SOT cohort, the overall response rate was 82%, and the two-year estimated overall survival was 81% [11] Market Data and Key Metrics Changes - The potential indication for tab-cel in relapsed refractory PTLD is considered an ultra-rare disease, with several hundred patients in the U.S. and a similar number in Europe [55] - The company anticipates that the multi-cohort study planned for the second half of 2020 could lead to up to six additional indications, increasing the treatable population by at least a factor of four [55] Company Strategy and Development Direction - Atara is focused on advancing its T-cell immunotherapy programs, particularly the tab-cel platform, and has extended its cash runway into Q2 2021 [8][21] - The company aims to leverage its manufacturing capabilities to create a competitive advantage in off-the-shelf, allogeneic T-cell immunotherapy [20][72] - Atara is also exploring partnerships to access its off-the-shelf T-cell platform and other product portfolios [20][73] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress made in 2019 and the positioning for success in 2020, particularly regarding key milestones for tab-cel [22] - The company is optimistic about the potential of its innovative therapies and the interest from potential partners [20][73] Other Important Information - Atara has appointed Kristin Yarema as the new Chief Commercial Officer, bringing extensive experience in hematology, oncology, and autoimmune disease commercialization [20] - The company is on track to initiate enrollment for a randomized, placebo-controlled Phase 1b study of ATA188 in the second or third quarter of 2020 [16] Q&A Session Summary Question: Update on tab-cel enrollment and interim analysis - Management confirmed that they are not commenting on enrollment at this stage but reiterated plans to initiate BLA filing in the second half of 2020 following a pre-BLA meeting with the FDA [25][26] Question: Target number of trial sites for tab-cel - Currently, there are 38 sites open in the U.S., and the company anticipates enrolling up to 24 sites in Europe [33] Question: Data release timeline for ATA188 - Six-month data for all cohorts is expected in the first half of 2020, with 12-month data for the first three cohorts anticipated in the second half of 2020 [35] Question: Timing for results from the nasopharyngeal carcinoma study - The final patient has been enrolled, and results will be evaluated as the landscape matures [40] Question: Market size for EBV+ relapsed refractory PTLD - The company estimates several hundred patients in the U.S. and Europe could benefit from tab-cel, with plans for additional indications to increase the treatable population [55]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-0920988 (State or other jurisdic ...

Financial Data and Key Metrics Changes - The company ended Q3 2019 with a cash balance of $282.9 million, reflecting proceeds from a recent secondary follow-on financing, and expects to have sufficient cash to fund operations through 2021 [19]. Business Line Data and Key Metrics Changes - Tab-cel demonstrated an overall response rate of 55% in hematopoietic cell transplant (HCT) patients and 82% in solid organ transplant (SOT) patients, with estimated two-year overall survival rates of 79% for HCT and 81% for SOT [10][11]. - The company is on track to initiate Biologics License Application (BLA) submissions for tab-cel in the second half of 2020, with 35 sites available for enrollment in the U.S. and Australia [11][12]. Market Data and Key Metrics Changes - The potential U.S. market for tab-cel in relapsed/refractory EBV+ PTLD is estimated to be several hundred patients per year, with additional opportunities in Europe [14]. Company Strategy and Development Direction - The strategic objective is to become the leading off-the-shelf allogeneic T-cell immunotherapy company, focusing on four priorities: filing and launching tab-cel, achieving clinical proof of concept with ATA188, advancing mesothelin programs, and developing ATA3219 for B-cell malignancies [8][9]. - The company plans to leverage external partners for autologous CAR T immunotherapy development while focusing on allogeneic therapies [9]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term outcomes of tab-cel, emphasizing its potential as a transformative therapy for patients with relapsed/refractory EBV+ PTLD [10][11]. - The company is actively engaging with the European Medicines Agency (EMA) to determine the timing of the tab-cel EU conditional marketing authorization application [12]. Other Important Information - The company has completed facility commissioning and qualification activities to support clinical development at its operations and manufacturing facility [19]. - The management team is adapting to new strategic priorities, including searches for key leadership positions [19]. Q&A Session Summary Question: What gives confidence to move forward with ATA188 based on six-month data? - Management highlighted that cohort 3 met predetermined criteria with a well-tolerated safety profile and clinical improvement in at least 50% of patients, justifying the decision to proceed [22][23][24]. Question: What is the timeline for opening more clinical sites in Canada and the U.S.? - Enrollment is progressing as planned, with efforts to increase the number of sites in the U.S. and Canada, and a CTA filing in Europe is expected by the end of the year [27][28]. Question: Why is only 10% of U.S. centers involved in the trials? - The focus is on optimizing top centers that are geographically suited and seeing the most patients, rather than opening all available centers [37][38]. Question: What is the strategy for the CD19 allogeneic CAR-T program? - The company aims to demonstrate that its EBV-based allogeneic CAR-T can provide a safe and effective treatment option, with a focus on rapid clinical development [59][60]. Question: How many patients have been treated in the expanded access program for tab-cel? - While specific numbers were not disclosed, management indicated that data from the expanded access program will inform future studies and updates will be provided at future congresses [75].

[PART I. FINANCIAL INFORMATION](index=3&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements (Unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) The company reported a Q3 2019 net loss of $71.9 million and held $282.9 million in cash and investments amid significant R&D spending [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets were $364.8 million as of September 30, 2019, with total stockholders' equity at $318.4 million Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2019 | Dec 31, 2018 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $94,431 | $60,698 | | Short-term investments | $188,491 | $248,933 | | Total current assets | $293,418 | $321,489 | | Total assets | $364,785 | $391,839 | | **Liabilities & Equity** | | | | Total current liabilities | $30,706 | $39,979 | | Total liabilities | $46,343 | $52,982 | | Total stockholders' equity | $318,442 | $338,857 | | Total liabilities and stockholders' equity | $364,785 | $391,839 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) The company's net loss increased to $71.9 million in Q3 2019, driven by higher research, development, and administrative expenses Statement of Operations Highlights (in thousands, except per share data) | Metric | Q3 2019 | Q3 2018 | Nine Months 2019 | Nine Months 2018 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $53,538 | $43,355 | $154,457 | $105,202 | | General and administrative | $19,018 | $16,865 | $61,525 | $50,093 | | **Loss from operations** | **($72,556)** | **($60,220)** | **($215,982)** | **($155,295)** | | **Net loss** | **($71,895)** | **($58,361)** | **($212,480)** | **($150,687)** | | Net loss per share | ($1.31) | ($1.29) | ($4.32) | ($3.49) | [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations was $176.9 million for the nine-month period, offset by $151.3 million raised from financing activities Cash Flow Summary (Nine Months Ended Sep 30, in thousands) | Activity | 2019 | 2018 | | :--- | :--- | :--- | | Net cash used in operating activities | ($176,936) | ($122,353) | | Net cash provided by (used in) investing activities | $59,332 | ($242,357) | | Net cash provided by financing activities | $151,337 | $351,515 | | **Net increase (decrease) in cash** | **$33,733** | **($13,195)** | [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail the company's operating losses, reliance on equity financing, and adoption of the new lease standard ASC 842 - Atara is a clinical-stage allogeneic T-cell immunotherapy company developing treatments for cancer, autoimmune, and viral diseases with an **accumulated deficit of $739.5 million** as of September 30, 2019[17](index=17&type=chunk)[19](index=19&type=chunk) - The company adopted the new lease accounting standard (ASU 2016-02, Topic 842) on January 1, 2019, recognizing **operating lease assets of $14.3 million** and liabilities of $15.3 million[33](index=33&type=chunk)[34](index=34&type=chunk) - In July 2019, the company raised **gross proceeds of $150.0 million** ($140.7 million net) through an underwritten public offering of common stock and pre-funded warrants[77](index=77&type=chunk) - The company utilizes an "at the market" (ATM) facility, selling 686,131 shares for **net proceeds of $12.6 million** during the first nine months of 2019[80](index=80&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses its focus on key T-cell programs, rising R&D costs, and its belief that cash is sufficient into 2021 - The company's strategic priorities are its most advanced T-cell immunotherapy programs: **Tab-cel® (Phase 3), ATA188, and next-generation CAR T programs**[98](index=98&type=chunk) - Atara plans to initiate a **Biologics License Application (BLA) submission for Tab-cel®** for patients with EBV+ PTLD in the second half of 2020[103](index=103&type=chunk) - The company expects its existing cash, cash equivalents, and short-term investments of **$282.9 million** (as of Sep 30, 2019) will be sufficient to fund planned operations into 2021[133](index=133&type=chunk)[141](index=141&type=chunk) Research & Development Expenses by Program (in thousands) | Program | Nine Months 2019 | Nine Months 2018 | Change | | :--- | :--- | :--- | :--- | | Tab-cel® expenses | $34,006 | $33,748 | $258 | | ATA188, ATA190, CAR T & other | $24,060 | $11,753 | $12,307 | | Employee and overhead | $96,391 | $59,701 | $36,690 | | **Total R&D Expenses** | **$154,457** | **$105,202** | **$49,255** | [Quantitative and Qualitative Disclosures about Market Risk](index=27&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company reports no material changes to its market risk disclosures during the nine months ended September 30, 2019 - There were **no material changes** to the company's market risk disclosures, including interest rate and foreign currency exchange rate risks, during the nine months ended September 30, 2019[148](index=148&type=chunk) [Controls and Procedures](index=28&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective with no material changes to internal controls - The CEO and CFO concluded that the company's **disclosure controls and procedures were effective** as of September 30, 2019[150](index=150&type=chunk) - **No changes in internal control over financial reporting** occurred during the quarter that materially affected, or are reasonably likely to materially affect, the company's internal controls[153](index=153&type=chunk) [PART II. OTHER INFORMATION](index=29&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=29&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any material legal proceedings - The company reports **no material legal proceedings**[155](index=155&type=chunk) [Risk Factors](index=29&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant financial, developmental, manufacturing, commercialization, and intellectual property risks - **Financial Risks:** The company has a history of substantial losses (**$739.5 million accumulated deficit**) and expects to incur increasing losses, requiring substantial additional financing[158](index=158&type=chunk)[165](index=165&type=chunk) - **Development & Regulatory Risks:** Product candidates are in early development and represent new therapeutic approaches (allogeneic T-cell therapy), facing **heightened regulatory scrutiny and potential trial failures**[171](index=171&type=chunk)[181](index=181&type=chunk) - **Manufacturing & Supply Risks:** The company is subject to significant manufacturing risks, including process scale-up and **reliance on its ATOM facility and third-party CMOs**[223](index=223&type=chunk)[229](index=229&type=chunk)[237](index=237&type=chunk) - **Commercialization Risks:** Success depends on market acceptance, obtaining adequate reimbursement, and **competing with established therapies** and companies with greater resources[274](index=274&type=chunk)[276](index=276&type=chunk)[288](index=288&type=chunk) - **Intellectual Property Risks:** The company **relies heavily on in-licensed patents** and know-how from partners like MSK, and losing these rights could significantly harm the business[246](index=246&type=chunk)[266](index=266&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=62&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities during the period - None reported[343](index=343&type=chunk) [Defaults Upon Senior Securities](index=62&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - None reported[343](index=343&type=chunk) [Mine Safety Disclosures](index=62&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[344](index=344&type=chunk) [Other Information](index=62&type=section&id=Item%205.%20Other%20Information) The company reports no other information - None reported[344](index=344&type=chunk) [Exhibits](index=62&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including corporate documents and required certifications

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q2 2019 Results Earnings Conference Call August 8, 2018 8:00 AM ET Company Participants John Craighead - Vice President of Investor Relations and Corporate Communications Pascal Touchon - President and Chief Executive Officer AJ Joshi - Chief Medical Officer Chris Haqq - Chief Scientific Officer Conference Call Participants Anupam Rama - JP Morgan John Newman - Canaccord Genuity Salim Syed - Mizohu Americas Matt Phipps - William Blair Philip Nadeau - Cowen and C ...

PART I. FINANCIAL INFORMATION [Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) The unaudited condensed consolidated financial statements for the period ended June 30, 2019, detail the company's financial position, operational results, and cash flows, showing a significant increase in net loss driven by higher research and development and general administrative expenses, a decrease in cash and short-term investments, and increased cash usage in operations Condensed Consolidated Balance Sheet Highlights (in thousands) | Balance Sheet Item | June 30, 2019 | December 31, 2018 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $59,159 | $60,698 | | Short-term investments | $130,976 | $248,933 | | Total current assets | $201,139 | $321,489 | | Total assets | $274,144 | $391,839 | | **Liabilities & Equity** | | | | Total current liabilities | $25,803 | $39,979 | | Total liabilities | $41,865 | $52,982 | | Total stockholders' equity | $232,279 | $338,857 | | Total liabilities and stockholders' equity | $274,144 | $391,839 | Statement of Operations Highlights (in thousands, except per share data) | Metric | Three Months Ended June 30, 2019 | Three Months Ended June 30, 2018 | Six Months Ended June 30, 2019 | Six Months Ended June 30, 2018 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $52,251 | $33,387 | $100,919 | $61,847 | | General and administrative | $23,284 | $19,236 | $42,507 | $33,228 | | Loss from operations | ($75,535) | ($52,623) | ($143,426) | ($95,075) | | Net loss | ($74,328) | ($50,883) | ($140,585) | ($92,326) | | Basic and diluted net loss per share | ($1.60) | ($1.15) | ($3.04) | ($2.20) | Cash Flow Summary (in thousands) | Activity | Six Months Ended June 30, 2019 | Six Months Ended June 30, 2018 | | :--- | :--- | :--- | | Net cash used in operating activities | ($124,789) | ($74,256) | | Net cash provided by (used in) investing activities | $117,849 | ($253,794) | | Net cash provided by financing activities | $5,401 | $352,030 | | (Decrease) increase in cash, cash equivalents and restricted cash | ($1,539) | $23,980 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's business strategy, pipeline progress, financial results, and liquidity, highlighting the advancement of tab-cel® through **Phase 3** trials, significant increases in operating expenses, and the expectation that a July **2019** public offering will fund operations into **2021** Overview and Pipeline Atara is a leading **allogeneic T-cell immunotherapies** company with a platform focused on cancer, autoimmune, and viral diseases, advancing tab-cel® in **Phase 3** for EBV+ PTLD with a planned **BLA submission** in the second half of **2020**, and developing ATA188/190 for multiple sclerosis and a next-generation CAR T program - The company's lead product, tab-cel®, is in **Phase 3** development for EBV+ PTLD, with plans to initiate a Biologics License Application (**BLA submission**) in the second half of **2020**[91](index=91&type=chunk)[92](index=92&type=chunk) - The pipeline includes ATA188 (allogeneic) and ATA190 (autologous) for multiple sclerosis, with initial efficacy results for ATA188 expected in the second half of **2019**[96](index=96&type=chunk) - Atara is advancing a next-generation CAR T program, with an **IND planned** for autologous ATA2271 in advanced mesothelioma in **2020**[97](index=97&type=chunk)[98](index=98&type=chunk) Results of Operations For the three and six months ended June 30, 2019, operating expenses increased significantly compared to 2018, with research and development expenses rising to **$52.3 million** for the quarter and **$100.9 million** for the six-month period, driven by higher costs for tab-cel® **Phase 3** studies, ATA188/190 MS programs, and **increased headcount** Research and Development Expenses by Program (in thousands) | Program | Three Months Ended June 30, 2019 | Three Months Ended June 30, 2018 | Six Months Ended June 30, 2019 | Six Months Ended June 30, 2018 | | :--- | :--- | :--- | :--- | :--- | | Tab-cel® expenses | $11,252 | $8,089 | $22,891 | $17,134 | | ATA188, ATA190 and other | $9,102 | $6,855 | $15,208 | $11,179 | | Employee and overhead | $31,897 | $18,443 | $62,820 | $33,534 | | **Total R&D Expenses** | **$52,251** | **$33,387** | **$100,919** | **$61,847** | - General and administrative expenses increased to **$42.5 million** for the six months ended June 30, **2019**, from **$33.2 million** in the prior-year period, primarily due to **increased headcount** and related **compensation costs**[116](index=116&type=chunk) Liquidity and Capital Resources As of June 30, 2019, Atara had **$190.1 million** in cash, cash equivalents, and short-term investments, with management expecting that existing cash combined with **$140.6 million** in **net proceeds** from a July **2019** **underwritten public offering** will be **sufficient to fund planned operations** into **2021** - The company completed an **underwritten public offering** in July **2019**, raising aggregate **net proceeds** of approximately **$140.6 million**[119](index=119&type=chunk) - Management expects that cash, cash equivalents, and short-term investments as of June 30, **2019**, together with the proceeds from the July **2019** offering, will be **sufficient to fund planned operations** into **2021**[121](index=121&type=chunk)[129](index=129&type=chunk) - During the first six months of **2019**, the company sold **359,234** shares under its **ATM Facility** for **gross proceeds** of **$8.0 million**[118](index=118&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=27&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company states that there were no **material changes** to its market risk disclosures, including interest rate risk and foreign currency exchange rate risk, during the six months ended June 30, 2019, from what was reported in its **2018** Annual Report on Form **10-K** - There were **no material changes** to the company's market risk disclosures regarding interest rate and foreign currency exchange rate risk during the six months ended June 30, **2019**[138](index=138&type=chunk) [Controls and Procedures](index=27&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, evaluated the company's **disclosure controls and procedures** and concluded they were **effective** as of June 30, 2019, with no changes in **internal control over financial reporting** during the quarter that materially affected, or are reasonably likely to materially affect, these controls - The Chief Executive Officer and Chief Financial Officer concluded that the company's **disclosure controls and procedures** were **effective** as of June 30, **2019**[139](index=139&type=chunk) - No changes in **internal control over financial reporting** occurred during the six months ended June 30, **2019**, that have **materially affected**, or are reasonably likely to materially affect, internal controls[142](index=142&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=29&type=section&id=Item%201.%20Legal%20Proceedings) The company reports that it is **not currently involved** in any **material legal proceedings** - The company reports **no material legal proceedings**[144](index=144&type=chunk) [Risk Factors](index=29&type=section&id=Item%201A.%20Risk%20Factors) This section details numerous risks that could materially harm the company's business, including a history of **substantial financial losses** and the **need for additional capital**, the **unproven nature** of its T-cell immunotherapy platform, reliance on third parties for manufacturing, challenges in protecting intellectual property, and significant competition - Financial risks include a history of **substantial losses** (**$667.6 million** **accumulated deficit** as of June 30, **2019**) and the **need for substantial additional financing** to achieve goals[147](index=147&type=chunk)[154](index=154&type=chunk) - Development risks center on the novel and **unproven nature** of T-cell immunotherapy, which could result in **heightened regulatory scrutiny**, **clinical trial delays**, or **failure to receive approval**[170](index=170&type=chunk) - The company faces **manufacturing risks** related to **scaling up complex cellular therapy processes**, **potential contamination**, and **reliance on a limited number of contract manufacturing organizations (CMOs)**[210](index=210&type=chunk)[213](index=213&type=chunk) - Commercialization success depends on gaining **market acceptance**, securing **adequate reimbursement** from payors, and **competing with established therapies** and companies with **greater resources**[258](index=258&type=chunk)[260](index=260&type=chunk)[272](index=272&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=61&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports **no unregistered sales** of equity securities during the period - **None reported**[323](index=323&type=chunk) [Defaults Upon Senior Securities](index=61&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports **no defaults** upon senior securities - **None reported**[323](index=323&type=chunk) [Mine Safety Disclosures](index=61&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is **not applicable** to the company - **Not applicable**[324](index=324&type=chunk) [Other Information](index=61&type=section&id=Item%205.%20Other%20Information) The company reports **no other information** for this period - **None reported**[324](index=324&type=chunk) [Exhibits](index=62&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Quarterly Report on Form **10-Q**, including the company's amended and restated certificate of incorporation and bylaws, executive employment agreements, and certifications by the CEO and CFO

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants John Craighead - Vice President of Investor Relations and Corporate Communications Isaac Ciechanover - President and Chief Executive Officer Dietmar Berger - Global Head of Research and Development Utpal Koppikar - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan John Newman - Canaccord Salim Syed - Mizuho Matt Phipps - William Blair Maryana Breitman - Goldman Sac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 | --- | --- | |------------------------------------------------------------------------------|--------------------------------------- ...